{
    "2020-11-10": [
        [
            {
                "time": "2018-01-02",
                "original_text": "Glaukos (GKOS) Beats Estimates on Narrower-than-Expected Loss (revised)",
                "features": {
                    "keywords": [
                        "Beats",
                        "Estimates",
                        "Narrower-than-Expected",
                        "Loss"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-03",
                "original_text": "Hill-Rom (HRC) Q4 Earnings, Revenues Top Estimates, Fall Y/Y",
                "features": {
                    "keywords": [
                        "Q4",
                        "Earnings",
                        "Revenues",
                        "Top",
                        "Estimates",
                        "Fall",
                        "Y/Y"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "mixed",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-04",
                "original_text": "Glaukos (GKOS) Gains 11.8% Despite Reporting Loss in Q3",
                "features": {
                    "keywords": [
                        "Gains",
                        "Reporting",
                        "Loss",
                        "Q3"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-05",
                "original_text": "Myriad Genetics (MYGN) Q1 Earnings & Revenues Top Estimates",
                "features": {
                    "keywords": [
                        "Q1",
                        "Earnings",
                        "Revenues",
                        "Top",
                        "Estimates"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-06",
                "original_text": "Oxford ups COVID-19 testing capacity with Thermo Fisher deal",
                "features": {
                    "keywords": [
                        "Oxford",
                        "COVID-19",
                        "testing",
                        "capacity",
                        "Thermo",
                        "Fisher",
                        "deal"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotech",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-07",
                "original_text": "Luminex (LMNX) Declines 6.6% as Q3 Earnings Miss Estimates",
                "features": {
                    "keywords": [
                        "Declines",
                        "Q3",
                        "Earnings",
                        "Miss",
                        "Estimates"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}